Estadísticas

 array:20 [
  "pii" => "X1665920109500716"
  "issn" => "16659201"
  "estado" => "S300"
  "fechaPublicacion" => "2009-07-01"
  "documento" => "article"
  "crossmark" => 0
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "GAMO. 2009;8 Supl 3:81-6"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 2554
    "formatos" => array:3 [
      "EPUB" => 50
      "HTML" => 1700
      "PDF" => 804
    ]
  ]
  "itemSiguiente" => array:16 [
    "pii" => "X1665920109500724"
    "issn" => "16659201"
    "estado" => "S300"
    "fechaPublicacion" => "2009-07-01"
    "documento" => "article"
    "crossmark" => 0
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "GAMO. 2009;8 Supl 3:87-9"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1597
      "formatos" => array:3 [
        "EPUB" => 23
        "HTML" => 1084
        "PDF" => 490
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Estrategias de prevención en pacientes oncológicos tratados con antraciclinas"
      "tienePdf" => "es"
      "tieneTextoCompleto" => 0
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "87"
          "paginaFinal" => "89"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Preventive strategies in oncologic patients treated with anthracyclines"
        ]
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Alejandra Meaney, Eduardo Meaney, Guillermo Ceballos"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "Alejandra"
              "apellidos" => "Meaney"
            ]
            1 => array:2 [
              "nombre" => "Eduardo"
              "apellidos" => "Meaney"
            ]
            2 => array:2 [
              "nombre" => "Guillermo"
              "apellidos" => "Ceballos"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X1665920109500724?idApp=UINPBA00004N"
    "url" => "/16659201/00000008000000S3/v0_201306121413/X1665920109500724/v0_201306121413/es/main.assets"
  ]
  "itemAnterior" => array:16 [
    "pii" => "X1665920109500708"
    "issn" => "16659201"
    "estado" => "S300"
    "fechaPublicacion" => "2009-07-01"
    "documento" => "article"
    "crossmark" => 0
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "GAMO. 2009;8 Supl 3:78-80"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 1363
      "formatos" => array:3 [
        "EPUB" => 36
        "HTML" => 953
        "PDF" => 374
      ]
    ]
    "es" => array:10 [
      "idiomaDefecto" => true
      "titulo" => "Cardioprotección en el niño con síndrome de Down"
      "tienePdf" => "es"
      "tieneTextoCompleto" => 0
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "78"
          "paginaFinal" => "80"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Cardioprotection in Down syndrome"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Enrique López Aguilar"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Enrique"
              "apellidos" => "López Aguilar"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X1665920109500708?idApp=UINPBA00004N"
    "url" => "/16659201/00000008000000S3/v0_201306121413/X1665920109500708/v0_201306121413/es/main.assets"
  ]
  "es" => array:11 [
    "idiomaDefecto" => true
    "titulo" => "Farmacoeconomía y cardioprotectores"
    "tieneTextoCompleto" => 0
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "81"
        "paginaFinal" => "86"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Amador Covarrubias Pinedo, Adriana Galaviz Muro, Benjamín Gálvez Gálvez"
        "autores" => array:3 [
          0 => array:3 [
            "nombre" => "Amador"
            "apellidos" => "Covarrubias Pinedo"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Adriana"
            "apellidos" => "Galaviz Muro"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "affb"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "Benjam&#237;n"
            "apellidos" => "G&#225;lvez G&#225;lvez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "affa"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Hospital Civil Dr. Juan I. Menchaca. Órgano Público Desconcentrado. Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara. Guadalajara, Jalisco, México."
            "etiqueta" => "<span class="elsevierStyleSup">a</span>"
            "identificador" => "affa"
          ]
          1 => array:3 [
            "entidad" => "Hospital Civil Dr. Juan I. Menchaca. Órgano Público Desconcentrado"
            "etiqueta" => "<span class="elsevierStyleSup">b</span>"
            "identificador" => "affb"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Pharmacoeconomic and cardioprotectors"
      ]
    ]
    "pdfFichero" => "305v08nSupl.3a13150071pdf001.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec176523"
          "palabras" => array:1 [
            0 => "cardioprotecci&#243;n&#44; farmacoeconom&#237;a&#44; quimioterapia&#44; M&#233;xico"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec176524"
          "palabras" => array:1 [
            0 => "cardioprotection&#44; pharmacoeconomic&#44; chemotherapy&#44; Mexico"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:1 [
        "resumen" => "La farmacoeconom&#237;a es la ciencia que analiza los gastos generados por el uso de f&#225;rmacos&#44; no s&#243;lo el costo que generan sino de la utilidad cl&#237;nica&#44; la eficacia&#44; la efectividad&#44; la eficiencia y la seguridad&#46; Durante la administraci&#243;n de quimioterapia se observan muchas complicaciones relacionadas con los medicamentos utilizados&#44; la cardiotoxicidad es una de las complicaciones m&#225;s alarmantes que ocasiona la muerte o da&#241;o cardiaco en pacientes que reciben quimioterapia&#46; La cardioprotecci&#243;n parece ser efectiva en la prevenci&#243;n de complicaciones cardiacas con repercusiones cl&#237;nicas graves&#44; a pesar del alto costo para nuestro medio&#46; Conforme se identifiquen los pacientes con mayor riesgo de da&#241;o cardiaco&#44; la cardioprotecci&#243;n ser&#225; mejor dirigida y se podr&#225;n optimizar recursos en beneficio de los pacientes&#46; Diferentes autores se&#241;alan que la mortalidad por da&#241;o cardiaco var&#237;a de 3&#37; a 6&#37; y la afectaci&#243;n cardiaca cl&#237;nica o subcl&#237;nica puede variar de 20&#37; a 50&#37;&#46; Sus manifestaciones son graves en un porcentaje elevado y la cardioprotecci&#243;n permite disminuir&#44; significativamente&#44; estos porcentajes&#46; Hacen falta m&#225;s estudios para tener conclusiones m&#225;s precisas&#46; Sin embargo&#44; con los datos disponibles se puede calcular que la cardioprotecci&#243;n disminuye significativamente el da&#241;o producido por la quimioterapia permitiendo aumentar las dosis para manejar mejor la enfermedad&#46;"
      ]
      "en" => array:1 [
        "resumen" => "Pharmacoeconomics is the science that analyzes the expenses generated by drug use&#44; not only the cost that these generate but of the clinical utility&#44; the effectiveness&#44; the efficiency and the security&#46; During chemotherapy administration a great number of drug related complications develop&#46; Cardiotoxicity is one of the most alarming complications&#44; it causes death or cardiac damage in patients who receive chemotherapy&#46; Cardioprotection seems to be effective in the prevention of these serious complications&#44; in spite of being of a high cost for our means&#46; In patients at increased risk of cardiac damage&#44; cardioprotection shall be intended and these resources should be optimized&#46; Different au thors indicate that cardiac related mortality varies from 3&#37; to 6&#37; and that the clinical or subclinical heart toxicity can vary from 20&#37; to 50&#37;&#46; Their manifestations are serious in a high percentage and the cardioprotection allows reducing&#44; significantly&#44; this percentage&#46; There is need for more studies to make solid conclusions&#46; Nevertheless&#44; with the available data it can calculate that the cardioprotection significantly diminishes the damage produced by the chemotherapy and allows increasing the doses of chemotherapy for the best handling of the disease&#46;"
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/16659201/00000008000000S3/v0_201306121413/X1665920109500716/v0_201306121413/es/main.assets"
  "Apartado" => array:4 [
    "identificador" => "11782"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Gu&#237;as para la prevenci&#243;n de la cardiotoxicidad en oncolog&#237;a y hematolog&#237;a"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/16659201/00000008000000S3/v0_201306121413/X1665920109500716/v0_201306121413/es/305v08nSupl.3a13150071pdf001.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X1665920109500716?idApp=UINPBA00004N"
]